NOV 08, 2013 12:00 PM PST

Childhood cancer with various genomic assay including whole genome sequencing

2 38 879

  • Scientific Projects Manager, TARGET, NCI Office of Cancer Genomics
      Dr. Guidry Auvil is a scientific program officer overseeing large-scale genomics efforts within the Office of Cancer Genomics at the National Cancer Institute.  She completed her doctoral work in the Biomedical Sciences program and received her PhD in tumor biology at Georgetown University.  In graduate school, Dr. Guidry Auvil studied the effects of cellular adhesion molecules on breast cancer bone metastases and holds a patent for a viable small molecule inhibitor of cadherin-11, which is currently being tested for various therapeutic applications. She also has a background in clinical and psychosocial research and project management in both the biotechnology and healthcare sectors. Dr. Guidry Auvil now manages the NCI pediatric cancer genomics initiative, Therapeutically Applicable Research to Generate Effective Treatments (TARGET).    
      <br />


    The NCI's Therapeutically Applicable Research to Generate Effective Treatments (TARGET) is a comprehensive genomic characterization initiative to determine the molecular changes that drive the development and progression of certain childhood cancers. TARGET seeks to improve treatment of these cancers through identification of valid molecular targets, in and across each disease, and ultimately lead to the rapid development of novel, more effective therapies. The TARGET projects include primarily high-risk for relapse cases. Most TARGET disease groups also have relapse samples available for study, thereby allowing the determination of changes that occur during the disease progression. To accelerate translation into the clinic, TARGET data is readily available to the research community for further investigation. There are currently around 2,000 TARGET BAM files from next generation platforms currently available to investigators, and additional sequencing files are regularly being submitted to expand the TARGET datasets. All TARGET cases have either whole genome or exome sequencing of matched tumor and normal pairs (relapse sample when available), and transcriptome sequences exist for most TARGET cases as well. In addition, all TARGET cases have clinical annotation, array-based gene expression and copy number data available to researchers, most also have methylation profiles, to allow for a more complete understanding of the molecular basis of these childhood cancers. Some projects have further included miRNA characterization data as well.

    Show Resources
    Loading Comments...